ER signaling is a critical target in breast cancer therapy, with selective estrogen receptor modulators (SERMs), selective estrogen receptor degraders (SERDs), and aromatase inhibitors (AIs) serving as the foundation for adjuvant treatment for ER+ breast cancer. The gene discussed is CYP19A1; the disease is breast carcinoma.